Glucose Bioluz

Glucose Bioluz is an intravenous solution containing glucose as the active ingredient. It is supplied in a sterile liquid form for parenteral administration, marketed in the European Union and available by prescription. The product provides a carbohydrate source for energy and fluid replacement when given intravenously. Each vial is designed for aseptic use and may be combined with other compatible IV fluids as part of a comprehensive nutrition regimen.

Glucose Bioluz is indicated for several clinical situations where rapid carbohydrate delivery and fluid balance are required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Provision of calories in patients receiving parenteral nutrition. - Fluid and electrolyte replacement in dehydration or postoperative care. - Support during surgery or critical illness when enteral feeding is contraindicated. - Dilution and compatibility with other intravenous medications as directed by clinical protocols.

When administered intravenously, Glucose Bioluz may be associated with a range of adverse effects, which are generally categorized by frequency and severity.

Common: - Mild hyperglycemia observed in patients with limited insulin response. - Transient nausea or vomiting related to rapid infusion rates. - Local irritation or pain at the infusion site. - Electrolyte shifts, particularly mild hyponatremia, due to dilutional effects.

Serious: - Severe hyperglycemia leading to osmotic diuresis and dehydration. - Hypersensitivity reactions, including rash, urticaria, or anaphylaxis. - Hyperosmolar hyperglycemic state in susceptible individuals. - Fluid overload causing pulmonary edema, especially in patients with cardiac dysfunction.

Clinicians should evaluate patient-specific factors before initiating Glucose Bioluz therapy to minimize risks and ensure appropriate use.

- Assess blood glucose levels and adjust infusion rates in diabetic patients. - Monitor fluid balance and weight to avoid overload in heart or kidney disease. - Use caution in patients with known hypersensitivity to glucose solutions. - Verify compatibility with other IV drugs to prevent precipitation or instability. - Adjust electrolyte supplementation as needed due to dilutional changes. - Follow aseptic technique to reduce the risk of catheter‑related infections.

Glucose Bioluz can interact with other intravenously administered agents, influencing their efficacy or safety profile.

Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring. - Simultaneous infusion of incompatible solutions such as calcium chloride or certain antibiotics that may precipitate. - Use with dextrose‑containing parenteral nutrition formulas that could cause excessive carbohydrate load.

Use with caution: - Concurrent administration of diuretics, which may exacerbate electrolyte disturbances. - Combination with vasopressors, requiring careful monitoring of hemodynamic status. - Infusion alongside blood products, as glucose may affect cell viability and storage conditions.